| scholarly article | Q13442814 |
| P50 | author | Giles J. Toogood | Q47319809 |
| Graham P. Cook | Q50980658 | ||
| Karen Scott | Q56441180 | ||
| Peter Selby | Q46220287 | ||
| P2093 | author name string | Richard Vile | |
| Hardev Pandha | |||
| Kevin J Harrington | |||
| Alan A Melcher | |||
| Matt Coffey | |||
| Fiona Errington-Mais | |||
| Robert A Adair | |||
| Sheila Fraser | |||
| P2860 | cites work | Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients | Q24617027 |
| Validation of a model of colon cancer progression. | Q53436811 | ||
| A study of human reovirus IgG and IgA antibodies by ELISA and western blot | Q72108362 | ||
| Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy | Q80162686 | ||
| Reovirus therapy in cancer: has the orphan virus found a home? | Q82623931 | ||
| Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics | Q27690634 | ||
| Junction adhesion molecule is a receptor for reovirus | Q28203704 | ||
| Genetic and Chemical Models of Colorectal Cancer in Mice | Q33771627 | ||
| Recent clinical experience with oncolytic viruses. | Q34198918 | ||
| Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial | Q34759406 | ||
| Reovirus-induced apoptosis: A minireview | Q35135749 | ||
| Cross-talk between dendritic cells and natural killer cells in viral infection | Q35988431 | ||
| Innate immunity in the liver | Q36036373 | ||
| Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic. | Q36506689 | ||
| Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy | Q37120166 | ||
| Tumor infection by oncolytic reovirus primes adaptive antitumor immunity | Q37239555 | ||
| Oncolytic viruses: a novel form of immunotherapy | Q37300008 | ||
| Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors | Q37364079 | ||
| Cell carriers for oncolytic viruses: Fed Ex for cancer therapy | Q37582184 | ||
| REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer | Q37602536 | ||
| Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization | Q39578769 | ||
| Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming | Q39588655 | ||
| Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus | Q39802923 | ||
| Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication | Q39840716 | ||
| Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma | Q39874999 | ||
| Reovirus activates human dendritic cells to promote innate antitumor immunity | Q39990406 | ||
| Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity | Q39995496 | ||
| The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig-like receptors | Q40235867 | ||
| Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming | Q40379100 | ||
| A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer | Q40405703 | ||
| Oncolytic reovirus against ovarian and colon cancer. | Q40742634 | ||
| HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas | Q43050854 | ||
| Cellular carriers or free viruses? | Q45046793 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| cytotoxicity | Q246181 | ||
| Reovirus | Q69812835 | ||
| P304 | page(s) | 2327-2338 | |
| P577 | publication date | 2012-11-26 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells | |
| P478 | volume | 132 |
| Q55464219 | A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. |
| Q35224368 | A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report |
| Q91650568 | Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy |
| Q38924531 | Cell carriers for oncolytic viruses: current challenges and future directions |
| Q41621228 | Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. |
| Q35596563 | Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus |
| Q90204077 | ELUCIDATION OF REOVIRUS PHARMACODYNAMICS IN A PHASE I TRIAL IN PATIENTS WITH KRAS MUTATED COLORECTAL CANCER |
| Q38912287 | Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment |
| Q26775030 | Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? |
| Q35162284 | Immune cells: more than simple carriers for systemic delivery of oncolytic viruses |
| Q47234408 | Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. |
| Q35061974 | Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites |
| Q33870670 | Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease |
| Q35812675 | Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia |
| Q35000631 | Oncolytic reovirus in canine mast cell tumor |
| Q47596708 | Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours. |
| Q38799217 | Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. |
| Q26775033 | Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants |
| Q91749359 | Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition |
| Q47160989 | Review: Oncolytic virotherapy, updates and future directions |
| Q35686522 | The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer |
| Q38360781 | The oncolytic virus, pelareorep, as a novel anticancer agent: a review |
| Q28072347 | Trial Watch-Oncolytic viruses and cancer therapy |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
Search more.